Ad
related to: nmo disease treatment mayo clinic children
Search results
Results from the WOW.Com Content Network
In 2002, Mayo Clinic researchers identified a humoral mechanism, targeting a perivascular protein, as the culprit of NMO, [26] and in 2004 an unknown specific autoantibody was found. [79] In 2005 they identified the aquaporin 4 protein as the target of the disease, and developed the first in-house test to aid in the diagnosis of NMO by ...
Schilder disease or diffuse myelinoclastic sclerosis: is a rare disease that presents clinically as a pseudotumoural demyelinating lesion; and is more common in children. [56] [57] Solitary sclerosis: This variant was proposed (2012) by Mayo Clinic researchers. [58] though it was also reported by other groups more or less at the same time.
Anti-MOG antibodies have been described in some patients with NMOSD [15] [16] who were negative for the aquaporin 4 (AQP-4) antibody. However, most NMOSD is an astrocytopathy, specifically an AQP4 antibody-associated disease, whereas MOG antibody-associated disease is an oligodendrocytopathy, suggesting that these are two separate pathologic entities. [2]
Neuromyelitis optica, or Devic's disease; Idiopathic inflammatory demyelinating diseases; Leukodystrophic or dysmyelinating disorders: CNS neuropathies such as those produced by vitamin B 12 deficiency; Central pontine myelinolysis; Myelopathies such as tabes dorsalis (syphilitic myelopathy) Leukoencephalopathies such as progressive multifocal ...
Diffuse myelinoclastic sclerosis, sometimes referred to as Schilder's disease, is a very infrequent neurodegenerative disease that presents clinically as pseudotumoural demyelinating lesions, making its diagnosis difficult. It usually begins in childhood, affecting children between 5 and 14 years old, [1] [2] but cases in adults are also ...
Dr. Nipunie Rajapakse, a pediatric infectious diseases physician with the Mayo Clinic Children's Center, tells Yahoo Life that norovirus is unrelated to influenza, despite its nickname. Instead ...
Satralizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody – people who are anti-aquaporin-4 or AQP4 antibody-positive. [6] [14] NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord. [6]
Anti-AQP4 diseases, are a group of diseases characterized by auto-antibodies against aquaporin 4. After the discovery of anti-AQP4 autoantibody in neuromyelitis optica , it was found that it was also present in some patients with other clinically defined diseases, including multiple sclerosis variants like optic-spinal MS .
Ad
related to: nmo disease treatment mayo clinic children